Skip to main content
Fig. 9 | Stem Cell Research & Therapy

Fig. 9

From: Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review

Fig. 9

source and manufacturing process, mainly the composition of medium; in terms of patients, including age, subtype and grading of GVHD, tissue damage degree of affected organs, and immune tolerance status of patients; in clinical trial design, including the timing, dosage and frequency of MSCs

Reasons for the inconsistent results of clinical trials involving MSC prevention or therapy for GVHD. In terms of MSCs, it includes the donor age, tissue

Back to article page